NKR 40: PICO 10 *Bør patienter med nyopståede lænderygsmerter tilbydes NSAID i tillæg til vanlig behandling?*

Review information

Authors

[Empty name][1]

[1][Empty affiliation]

Citation example: [Empty name]. NKR 40: PICO 10 *Bør patienter med nyopståede lænderygsmerter tilbydes NSAID i tillæg til vanlig behandling?*. Cochrane Database of Systematic Reviews [Year], Issue [Issue].

Abstract

Background

Objectives

Search methods

Selection criteria

Data collection and analysis

Main results

Authors' conclusions

Characteristics of studies

Characteristics of included studies

Hancock 2007

Methods	**Study design:** Randomized controlled trial **Study grouping:** Parallel group **Open Label:** **Cluster RCT:**
Participants	**Baseline Characteristics** Intervention Control **Included criteria:** All patients with low back pain (with or without leg pain)of less than 6 weeks duration presenting to any of40 participating GPs in Sydney, Australia, were invited toparticipate. The inclusion criterion was a complaint ofpain in the area between the 12th rib and buttock creasecausing moderate pain and moderate disability (measuredby adaptations of items 7 and 8 of SF-367). **Excluded criteria:** Exclusioncriteria were: present episode of pain not preceded by apain-free period of at least 1 month, in which care was notprovided; known or suspected serious spinal pathology;nerve root compromise (with at least two of these signs:myotomal weakness, dermatomal sensory loss, orhyporefl exia of the lower limb refl exes); presently takingNSAIDs or undergoing spinal manipulation; any spinalsurgery within the preceding 6 months; andcontraindication to paracetamol, diclofenac, or spinalmanipulative therapy. **Pretreatment:** Similar at baseline

Interventions	**Intervention Characteristics** Intervention ● *Diclofenac and Placebo manipulation*: ● *Placebo diclofenac and placebo manipulation*: Control ● *Diclofenac and Placebo manipulation*: ● *Placebo diclofenac and placebo manipulation*:
Outcomes	*Smerteintensitet (pain intensity) 0-12 uger* ● **Outcome type**: ContinuousOutcome ● **Reporting**: Fully reported ● **Scale**: NRS ● **Range**: 0-100 ● **Unit of measure**: none ● **Direction**: Lower is better ● **Data value**: Endpoint *Funktionsevne (Disability), 0-12 uger* ● **Outcome type**: ContinuousOutcome ● **Reporting**: Fully reported ● **Scale**: Roland Morris ● **Range**: 0-24 ● **Unit of measure**: none ● **Direction**: Lower is better ● **Data value**: Endpoint
Identification	**Sponsorship source:** The trial was mainly funded by Australia's National Health and MedicalResearch Council. The active diclofenac was donated by Alphapharm. **Country:** Australia **Setting:** GPs in Sydney, Australia **Comments:** **Authors name:** Mark Ha **Institution:** University of Sydney, Back Pain Research Group

	Email: M.Hancock@usyd.edu.au **Address:** Mark Hancock, University ofSydney, Back Pain ResearchGroup, PO Box 170, Lidcombe,NSW 1825, Australia
Notes	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Blinding of participants and personnel	Low risk	
Allocation concealment	Low risk	
Incomplete outcome data	Low risk	
Selective outcome reporting	Low risk	
Other sources of bias	Low risk	
Sequence Generation	Low risk	
Blinding of outcome assessors	Low risk	

Footnotes

References to studies

Included studies

Hancock 2007

Hancock M.J.; Maher C.G.; Latimer J.; McLachlan A.J.; Cooper C.W.; Day R.O.; Spindler M.F.; McAuley J.H.. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial. Lancet 2007;370(9599):1638-1643. [DOI:]

Data and analyses

1 Intervention vs Control

Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate
1.1 Smerteintensitet (pain intensity) 0-12 uger	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
1.1.1 Smerteintensitet (pain intensity) 0-12 uger	1	118	Mean Difference (IV, Fixed, 95% CI)	-0.08 [-0.75, 0.59]
1.2 Funktionsevne (Disability), 0-12 uger	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
1.2.1 Funktionsevne (Disability), 0-12 uger	1	117	Mean Difference (IV, Fixed, 95% CI)	-0.88 [-2.66, 0.90]

Figures

Figure 1 (Analysis 1.1)



Forest plot of comparison: 1 Intervention vs Control, outcome: 1.1 Smerteintensitet (pain intensity) 0-12 uger.